ADAR1 Capital Management »

Tg Therapeutics shares owned by ADAR1 Capital Management

Quarter-by-quarter ownership of Tg Therapeutics (TGTX) shares owned by ADAR1 Capital Management from 13F filings

Historical chart of ADAR1 Capital Management investment in Tg Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Tg Therapeutics held by ADAR1 Capital Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Tg Therapeutics by ADAR1 Capital Management

Quarter filed Position value Share count Share price at filing
2024-03-31 $66k 4.4k 15.21

More positions owned by ADAR1 Capital Management

Alnylam Pharmaceuticals (ALNY)
Ea Series Trust Alpha Arch 1-3 (BOXX)
Roivant Sciences SHS (ROIV)
Spdr S&p 500 Etf Tr Tr Unit Put Option (SPY)
Protagonist Therapeutics (PTGX)
Cytokinetics Com New (CYTK)
Keros Therapeutics (KROS)
Royalty Pharma Shs Class A (RPRX)
Bridgebio Pharma (BBIO)
Merrimack Pharmaceuticals In Com New
Ascendis Pharma A/s Sponsored Adr (ASND)
Arbutus Biopharma (ABUS)
Avrobio Ord (AVRO)
Beigene Sponsored Adr (BGNE)
Invesco Qqq Tr Unit Ser 1 Put Option (QQQ)

View all positions for ADAR1 Capital Management

Top funds holding Tg Therapeutics

BlackRock
Vanguard Group
BlackRock
State Street Corporation
Soleus Capital Management
Pictet Asset Management Holding SA
Geode Capital Management
Deep Track Capital
Woodline Partners
Susquehanna International
Opaleye Management
Goldman Sachs Group
Bank of America Corporation
Nuveen Asset Management
Morgan Stanley

View all funds holding Tg Therapeutics